In NSCLC patients with EGFR mutations and liver or brain metastases, the OS improvements were sustained in group treated with atezolizumab (PD-L1 antibody) plus bevacizumab and carboplatin (Reck et al. 2019). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.